Arranz Caso J A, López J C, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina J P, Fernández Guerrero M, Górgolas M
Infectious Diseases Unit, Hospital Príncipe de Asturias, Madrid, Spain.
HIV Med. 2005 Sep;6(5):353-9. doi: 10.1111/j.1468-1293.2005.00320.x.
To assess the antiviral efficacy and safety of switching from a protease inhibitor (PI) to nevirapine in patients with long-term HIV-1 RNA suppression on PI-containing regimens, and to assess its influence in the adherence to treatment.
In an open-label multicentre study, 160 HIV-infected patients with undetectable viral load for at least 6 months on a PI-containing regimen were randomized to either continue with their PI regimen (n=79) or replace PI with nevirapine (n=81). Clinical assessment included plasma HIV-1 RNA, blood chemistry, haematology, lymphocyte counts and adverse events reports. Adherence to treatment and lipodystrophy syndrome were assessed by patient self-reporting.
Treatment efficacy was equivalent in the two arms, for patients with viral loads either above or below 100 000 HIV-1 RNA copies/mL. The increase in CD4 cell count was significant in both arms (P<0.00001) but the average CD4 cell count at 48 weeks was slightly higher in the nevirapine arm (596 vs. 569; P=0.1588). The number of patients with severe hypertriglyceridaemia (>400 mg/dL) after 48 weeks of treatment decreased in the nevirapine arm (from 11 to six), but increased in the PI arm (from four to 11) and led to treatment discontinuation in two patients. Lipodystrophy changes increased in 15% of patients in the PI arm but decreased in 4% of patients in the nevirapine arm. Finally, although adherence was similar in the two arms, patients reported that it required significantly less effort to stay on treatment in the nevirapine arm. Conclusions The results indicate that switching from PI to nevirapine is as effective as continuing with PI for maintaining viral control, even in patients with baseline viral load above 100,000 copies/mL. In addition, reductions in hypertriglyceridaemia and lipodystrophy and in the effort required to stay on treatment were observed.
评估在含蛋白酶抑制剂(PI)方案治疗下长期实现HIV-1 RNA抑制的患者从PI转换为奈韦拉平的抗病毒疗效和安全性,并评估其对治疗依从性的影响。
在一项开放标签的多中心研究中,160例接受含PI方案治疗且病毒载量至少6个月检测不到的HIV感染患者被随机分为继续使用PI方案组(n = 79)或用奈韦拉平替代PI组(n = 81)。临床评估包括血浆HIV-1 RNA、血液化学、血液学、淋巴细胞计数及不良事件报告。通过患者自我报告评估治疗依从性和脂肪代谢障碍综合征。
对于病毒载量高于或低于100,000 HIV-1 RNA拷贝/mL的患者,两组的治疗效果相当。两组的CD4细胞计数均显著增加(P < 0.00001),但奈韦拉平组48周时的平均CD4细胞计数略高(596对569;P = 0.1588)。治疗48周后,奈韦拉平组严重高甘油三酯血症(>400 mg/dL)患者数量减少(从11例降至6例),而PI组增加(从4例增至11例),导致2例患者停药。PI组15%的患者脂肪代谢障碍变化增加,而奈韦拉平组4%的患者减少。最后,尽管两组的依从性相似,但患者报告称在奈韦拉平组坚持治疗所需的努力明显更少。结论结果表明,从PI转换为奈韦拉平在维持病毒控制方面与继续使用PI一样有效,即使对于基线病毒载量高于100,000拷贝/mL的患者也是如此。此外,还观察到高甘油三酯血症、脂肪代谢障碍以及坚持治疗所需努力的减少。